Beyond 510(k): Unlocking the Clinical Moat in Cardiac AI

The field of AI-driven diagnostics is rapidly maturing, and for astute venture capitalists and growth equity investors, a basic FDA 510(k) clearance is no longer a sufficient indicator of a strong clinical moat. While regulatory approval signals market entry, true defensibility and enterprise value in cardiac AI hinge on the depth, rigor, and real-world applicability of clinical evidence. This necessitates a more sophisticated framework for evaluating platforms, especially in high-stakes areas like coronary artery disease (CAD) diagnostics.

Beyond 510(k): The Evolving Bar for Clinical Validation

The initial wave of AI-enabled medical devices often leveraged the 510(k) pathway, demonstrating substantial equivalence to a predicate device. This regulatory mechanism, while efficient, primarily validates safety and foundational performance, not necessarily superior clinical outcomes or cost-effectiveness in a real-world setting. For diagnostic AI in cardiology, where patient management decisions carry significant weight, investors must probe deeper. The shift is towards understanding how an AI-native company’s solution genuinely alters clinical pathways, improves patient hard endpoints, and integrates smoothly into existing workflows. Consider the journey of an AI-native company. Their core product, data pipeline, and business model were built from inception around AI. This deep integration should translate into a superior ability to generate and use clinical evidence. However, not all AI-native approaches are created equal in their evidence generation strategies. The ideal scenario involves a continuous learning system operating within a Predetermined Change Control Plan (PCCP), allowing for iterative model improvements without constant re-submissions, all while demonstrating consistent or improved clinical utility.

Comparative Clinical Moats: Cleerly vs. HeartFlow

To illustrate the varying depths of clinical moats, let’s examine two prominent players in AI-driven CAD diagnostics: Cleerly and HeartFlow. Both use AI to provide insights from cardiac CT scans, but their approaches to clinical evidence and their respective impacts on patient management differ. HeartFlow, with its FFR-CT technology, provides a non-invasive assessment of fractional flow reserve (FFR) from standard coronary CT angiography (CCTA) images. This technology was designed to help clinicians determine the functional significance of coronary stenoses, potentially reducing the need for invasive angiography. HeartFlow’s clinical validation includes strong studies like the NXT and PACIFIC trials, which demonstrated high diagnostic accuracy in identifying hemodynamically significant CAD. The ADVANCE registry further examined the prognostic value of FFRCT and its impact on clinical outcomes and resource utilization HeartFlow ADVANCE registry clinical data. Their approach focuses on a quantifiable physiological metric, FFR, which has a well-established correlation with patient outcomes. The company has also built a significant patent thicket around CT-FFR, creating a substantial barrier to entry for competitors. Cleerly, on the other hand, focuses on quantitative coronary plaque analysis. Their FDA-cleared software measures and characterizes plaque volume, type, and vulnerability features from CCTA scans. The premise is that direct visualization and quantification of plaque, rather than just stenosis severity, can provide a more complete risk assessment and guide treatment decisions for individuals with CAD. Cleerly received its initial FDA 510(k) clearance for its Cleerly Labs v2.0 software for coronary plaque characterization and stenosis assessment in October 2020, and further clearances, including for its Cleerly ISCHEMIA software in September 2023, have followed Cleerly FDA 510(k) clearance dates. While their technology offers a compelling visual and quantitative assessment, the long-term impact on hard clinical endpoints (e.g., myocardial infarction, cardiac death) compared to standard care or other advanced diagnostics is an area of ongoing research and evidence building. The distinction lies not just in the “what” they measure, but “how” that measurement translates into a demonstrable improvement in patient outcomes and, importantly for investors, a defensible market position. HeartFlow’s focus on functional significance, backed by strong diagnostic accuracy data against invasive FFR, has allowed it to carve out a clear niche in the diagnostic pathway, often reducing downstream invasive procedures. Cleerly’s detailed plaque analysis offers a different, complementary perspective, but its clinical utility in altering management and improving hard outcomes, particularly in asymptomatic or mildly symptomatic populations, requires a sustained commitment to generating Real-World Evidence (RWE) and potentially new randomized controlled trials.

A 3-Part Framework for Evaluating Clinical Moat Rigor

For investors scrutinizing diagnostic imaging AI companies, a three-part framework can help assess the depth of their clinical moat, moving beyond mere regulatory clearance to true enterprise value.

1. Endpoint Alignment: Hard Outcomes vs. Surrogate Markers

The most strong clinical moats are built on evidence demonstrating improvement in hard clinical endpoints: mortality, myocardial infarction, stroke, or hospitalization. Diagnostic AI that reliably reduces these events or significantly delays their onset offers undeniable value.

• Tier 1: Hard Clinical Endpoints: Does the AI directly reduce mortality, MI, or other major adverse cardiovascular events (MACE)? Evidence from prospective, randomized controlled trials (RCTs) demonstrating this is the gold standard. For instance, an AI that accurately identifies patients who benefit from early intensive lipid-lowering therapy, leading to a measurable reduction in future MI, creates an exceptionally strong clinical moat.
• Tier 2: Validated Surrogate Endpoints: Does the AI improve established surrogate endpoints that are strongly correlated with hard outcomes? Examples include reducing the need for invasive procedures (like HeartFlow’s impact on invasive angiography) or improving diagnostic accuracy for conditions with clear treatment pathways. The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines often highlight such surrogate markers. ACC/AHA clinical guidelines on CAD diagnosis
• Tier 3: Mechanistic or Descriptive Endpoints: Does the AI provide novel insights (e.g., detailed plaque characterization by Cleerly) that are biologically plausible but whose direct impact on hard outcomes is still being elucidated? While valuable for research and potentially future drug development, these require a longer evidence-generation runway to establish a deep clinical moat from an investment perspective. Investors should look for a clear roadmap to demonstrating impact on higher-tier endpoints.
  

  2. Workflow Integration and Clinical Decision Impact

  An AI solution, however accurate, is only as valuable as its ability to integrate smoothly into clinical workflow and meaningfully influence physician decision-making.

• Smooth Integration: Does the AI fit naturally into existing diagnostic pathways, or does it require significant changes in clinician behavior or infrastructure? Products that augment current imaging interpretation without adding undue burden are more likely to achieve widespread adoption.
• Actionable Insights: Does the AI provide clear, unambiguous, and actionable insights that directly lead to changes in patient management? Vague or overly complex outputs can lead to “alert fatigue” or be ignored. The best AI acts as a clinical decision support tool that helps, rather than overwhelms, the clinician.
• Economic Value Proposition: Does the AI demonstrate clear cost savings or revenue generation opportunities for healthcare systems? This can include reducing unnecessary downstream tests, improving patient throughput, or enabling better resource allocation. Reimbursement pathway clarity, including CPT codes (Category I & III), is a critical component here.
  

  3. Evidence Generation Strategy and Regulatory Foresight

  The strength of a clinical moat is also a function of the company’s ongoing commitment to evidence generation and its proactive approach to regulatory evolution.

• Continuous RWE Generation: Is the company actively collecting and analyzing Real-World Evidence (RWE) from diverse patient populations to validate and refine its AI performance post-market? This is important for detecting and mitigating algorithmic drift.
• PCCP and Adaptive Learning: For AI/ML SaMD, does the company have an FDA-approved Predetermined Change Control Plan (PCCP) that allows for safe and effective model updates based on new data without requiring repeated 510(k) submissions? This signals a mature approach to adaptive learning and regulatory compliance.
• GMLP and QMS: Is the company adhering to Good Machine Learning Practice (GMLP) principles and maintaining a strong Quality Management System (QMS) (e.g., ISO 13485 certified)? These foundational elements underpin the trustworthiness and reliability of the AI. Investors should ask about GMLP compliance during diligence, as a lack thereof indicates significant regulatory debt.
  

  Conclusion

  For venture capitalists and growth equity investors evaluating diagnostic imaging AI companies, the era of “FDA cleared, therefore investable” is over. A deep clinical moat is not merely about regulatory badges, but about demonstrable, sustained impact on patient outcomes, smooth integration into clinical practice, and a rigorous, forward-looking approach to evidence generation. By applying a structured framework that scrutinizes endpoint alignment, workflow impact, and the underlying evidence strategy, investors can identify truly AI-native platforms poised for long-term commercial success and defensibility in the competitive field of cardiac AI.